| Assessment Status | |
| HTA ID | 22072 |
| Drug | Eladocagene exuparvovec |
| Brand | Upstaza® |
| Indication | For the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype. |
| Assessment Process | |
| Rapid review commissioned | 08/12/2022 |
| Rapid review completed | 23/12/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of eladocagene exuparvovec compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/02/2023 |
| Pre-submission consultation with Applicant | 18/04/2023 |
Not considered cost-effective due to non-submission of full HTA.